Previous Webinar

Research Professor (UNC) - Chief Scientist (SGC)

University of North Carolina at Chapel Hill

 tim.willson@unc.edu

 (919) 491-3177

Dr. Hisanori Matsui joined Takeda Pharmaceutical Company Limited in 2002. His experience includes early-stage target discovery, G-protein coupled receptors, Oncology, Endocrinology, Neuroendocrinology, Reproductive Biology, Drug Repurposing, and Translational Research. Dr. Matsui is currently leading Neuroscience external partnership with a particular emphasis of academic innovation toward delivering transformative and sustainable neuroscience pipelines. Dr. Matsui received his PhD in Biology from the University of Tsukuba in 2015. He is also Associate Professor of Biology, Graduate School of Science and Technology, University of Tsukuba.

Adrian Carter is vice president and global head of Discovery Research Coordination at Boehringer Ingelheim where he is responsible for guiding research policy and strategy, as well as steering operational themes. His career at Boehringer Ingelheim spans over 35 years and his interests include the neurobiology of dopamine, noradrenaline and acetylcholine release as well as the role of glutamate receptors and voltage-dependent sodium channels in health and disease.

Aled Edwards is the founding and current CEO of the Structural Genomics Consortium (SGC), a professor at the University of Toronto and an adjunct professor at McGill University. The SGC has been sharing its science freely since 2003 and is widely acknowledged as a pioneer in open science.

Cheryl is the Chief Scientist for the SGC Toronto laboratories, Professor of Medical Biophysics at the University of Toronto, Senior Scientist at the Ontario Cancer Institute/Princess Margaret Cancer Center, and Canada Research Chair in Structural Genomics. 

Cheryl obtained her PhD in chemistry at the University of Toronto and did postdoctoral training at Stanford in protein structural biology using NMR spectroscopy. Cheryl has studied the structure and function of transcription regulatory proteins such as the tumor suppressor, p53, and its regulators.  A long time collaborator of Aled Edwards (SGC Director), the pair teamed up in the late 1990’s to develop structural biology methods for genome-scale research -  a concept that grew into the field of Structural Genomics.

Hiroaki Suga is a Professor at the Department of Chemistry, Graduate School of Science, University of Tokyo. His research interests are in the field of bioorganic chemistry, chemical biology and biotechnology related to RNA, translation, and peptides. His lab utilizes organic chemistry techniques in combination with biology to tackle yet unresolved questions and develop novel technologies with broad applicability, which can be extended to drug discovery.

Co-Director, Australian Translational Medicinal Chemistry Facility, Lecturer, Monash Institute of Pharmaceutical Sciences

Core expertise

Molecular design
Peptidomimetics
Small molecule screening libraries and chemoinformatics
Hit-to-lead and lead optimisation medicinal chemistry
Drug discovery in infectious disease (particularly neglected diseases including malaria) and Epigenetic modulation associated with cancer
Pre-clinical development of new drug candidates

yoshidam@riken.jp

Chemical Genomics Research Group,
RIKEN Center for Sustainable Resource Science

2-1 Hirosawa, Wako, Saitama 351-0198 Japan